GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Herantis Pharma PLC (OHEL:HRTIS) » Definitions » PS Ratio

Herantis Pharma (OHEL:HRTIS) PS Ratio : (As of Dec. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Herantis Pharma PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Herantis Pharma's share price is €1.60. Herantis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00. Hence, Herantis Pharma's PS Ratio for today is .

The historical rank and industry rank for Herantis Pharma's PS Ratio or its related term are showing as below:

During the past 13 years, Herantis Pharma's highest PS Ratio was 1577.18. The lowest was 200.00. And the median was 583.32.

OHEL:HRTIS's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 8.73
* Ranked among companies with meaningful PS Ratio only.

Herantis Pharma's Revenue per Sharefor the six months ended in Jun. 2024 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00.

Back to Basics: PS Ratio


Herantis Pharma PS Ratio Historical Data

The historical data trend for Herantis Pharma's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Herantis Pharma PS Ratio Chart

Herantis Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Herantis Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Herantis Pharma's PS Ratio

For the Biotechnology subindustry, Herantis Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Herantis Pharma's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Herantis Pharma's PS Ratio distribution charts can be found below:

* The bar in red indicates where Herantis Pharma's PS Ratio falls into.



Herantis Pharma PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Herantis Pharma's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.60/0
=

Herantis Pharma's Share Price of today is €1.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Herantis Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Herantis Pharma  (OHEL:HRTIS) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Herantis Pharma PS Ratio Related Terms

Thank you for viewing the detailed overview of Herantis Pharma's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Herantis Pharma Business Description

Traded in Other Exchanges
N/A
Address
Bertel Jungin Aukio 1, Espoo, FIN, 02600
Herantis Pharma PLC is a biotech company developing disease-modifying therapies for Parkinson's disease. The company's current development program focuses solely on HER-096, which is a peptidomimetic molecule designed to retain the biological activity of the neuroprotective CDNF protein.

Herantis Pharma Headlines

No Headlines